Jim Myers || 17th January 2016 || News analysis || Policy and Politics | Geographies: North America United States
Robert Califf’s nomination to become the next commissioner of the U.S. Food and Drug Administration (FDA) has won an easy vote in a Senate committee – but may still face a roadblock that could delay the final approval of his appointment.
Are you already a subscriber? login here Enjoy free subscription access Get access to premium content that is normally only available for subscribers. For the duration of a week, you can read our news analysis, identify market trends and understand upcoming changes in the industry, which will enable you to get ahead of your competitors. Benefits of subscription plans: Stay informed of any legal and market change in the sector that impacts your organization Maximise resources by getting market and legal data analysis daily in one place Make smart decisions by understanding how the regulatory and market landscape evolves Anticipate risks in your decisions by monitoring regulatory changes that impact your organization